Medigene AG, a company specializing in immuno-oncology, has received a patent from the Chinese Patent Office for its T cell receptor (TCR) targeting NY-ESO-1 and LAGE 1a. These antigens are known to be associated with various types of solid tumors and have been extensively studied and validated. The patent protects Medigene’s innovative approach to developing T cell immunotherapies for these specific cancer antigens.
Selwyn Ho, CEO of Medigene AG, expressed excitement over the recent patent approval for their NY-ESO-1/LAGE1a-targeted TCR in China. This TCR, in combination with the PD1-41BB costimulatory switch protein, is a key component of their leading TCR-T program MDG1015, designed for the treatment of various cancers including gastric cancer, ovarian cancer, myxoid/round cell liposarcoma, and synovial sarcoma. The company is on track to submit a US IND application in the third quarter of the year. The approval in China adds to existing patents in the US, Europe, Japan, South Korea, Taiwan, and Australia, expanding the potential for the use of their optimal affinity 3S (sensitive, specific, and safe) TCRs globally in various therapeutic approaches, such as TCR-T therapies, TCR-guided T cell engagers, and TCR natural killer cell therapies.
Medigene is consistently broadening and reinforcing its range of patents by incorporating new technologies and expanding current patents to encompass more regions. With over 20 distinct patent families globally, Medigene safeguards its 3S TCRs and E2E Platform technologies through various applications.